Results 21 to 30 of about 1,950 (155)

Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis

European Journal of Medical Research, 2023
Background Roxadustat is a novel oral medication used to treat anemia in CKD patients. Several studies have shown that Roxadustat can alleviate anemia in CKD patients by increasing hemoglobin levels and regulating iron metabolism.
Yangyang Zhang, Liang Zhang, Pengcheng Ge, Ruyi Xu, Zhen Ye   +4 more
doaj   +1 more source

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease

Frontiers in Medicine, 2023
BackgroundWe determined the effects of roxadustat on the values of anemia, iron metabolism, renal function, proteinuria, and lipid metabolism and identified the associated factors of the change in hemoglobin levels after roxadustat administration in non ...
Keiji Hirai, Shohei Kaneko, Saori Minato, Katsunori Yanai, Momoko Hirata, Taisuke Kitano, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita   +9 more
doaj   +1 more source

Roxadustat for Patients with Posttransplant Anemia: A Narrative Review

Kidney Diseases, 2023
Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating anemia in chronic kidney disease patients, has been approved in ...
Xiaoxiao Tang, Fei Liu, Qiuyu Li, Jianhua Mao   +3 more
doaj   +1 more source

Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat

Frontiers in Pharmacology, 2021
Background: Roxadustat is a new oral drug for anemia in chronic kidney disease (CKD). This study aimed to synthesize the evidence from randomized controlled trial (RCT)-based studies that estimated the efficacy and safety of roxadustat in anemia patients
Mei Tang, Mei Tang, Changyu Zhu, Changyu Zhu, Ting Yan, Ting Yan, Yanglin Zhou, Yanglin Zhou, Qin Lv, Junlan Chuan, Junlan Chuan   +10 more
doaj   +1 more source

Roxadustat: Do we know all the answers? [PDF]

, 2023
Anemia is a common complication of chronic kidney disease (CKD), and its prevalence rises as the disease progresses. Intravenous or subcutaneous erythropoiesis-stimulating agents (ESAs) are advised to treat CKD-associated anemia, since shortage of ...
Jianhua Mao, Tong Tong, Fei Liu, Wan-Xin Peng, Xuefeng Yao, Li, Qiu-Yu, Fu, Haidong, Mao, Jianhua, Xiaoxiao Tang, Qiu-Yu Li, Yao, Xuefeng, Xiong, Qian-Wen, Liu, Fei, Tong, Tong, Peng, Wan-Xin, Tang, Xiaoxiao, Haidong Fu, Qian-Wen Xiong   +17 more
core   +1 more source

Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis

BMC Nephrology, 2021
Background Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) is a novel choice for the treatment of renal anemia, and an oral HIF-PH inhibitor roxadustat was approved for renal anemia.
Mitsuru Ichii, Katsuhito Mori, Daichi Miyaoka, Mika Sonoda, Yoshihiro Tsujimoto, Shinya Nakatani, Tetsuo Shoji, Masanori Emoto   +7 more
doaj   +1 more source

Roxadustat, a Hypoxia-Inducible Factor 1α Activator, Attenuates Both Long- and Short-Term Alcohol-Induced Alcoholic Liver Disease

Frontiers in Pharmacology, 2022
Alcoholic liver disease (ALD) is a worldwide healthcare problem featured by inflammation, reactive oxygen species (ROS), and lipid dysregulation. Roxadustat is used for chronic kidney disease anemia treatment.
Yongyao Gao, Xiaomeng Jiang, Daigang Yang, Wentong Guo, Dandan Wang, Ke Gong, Ying Peng, Hong Jiang, Cunyuan Shi, Yajun Duan, Yuanli Chen, Jihong Han, Jihong Han, Xiaoxiao Yang   +13 more
doaj   +1 more source

A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness [PDF]

The Korean Journal of Internal Medicine
Background/Aims Roxadustat, an oral medication for treating renal anemia, is a hypoxia-inducible factor prolyl hydroxylase inhibitor used for regulating iron metabolism and promoting erythropoiesis. To investigate the efficacy and safety of roxadustat in
Jie Liu, Shuang Li, Fan Yang, Tianyu Li, Rui Li, Yousuf Waheed, Chen Meng, Shulin Li, Kun Liu, Yanshan Tong, Haisheng Xu, Chuankuo Tian, Xinglei Zhou   +12 more
doaj   +1 more source

Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis

Frontiers in Pharmacology, 2022
Background: Many studies demonstrated that roxadustat (FG-4592) could increase hemoglobin (Hb) levels effectively in anemia patients with chronic kidney disease (CKD). However, its safety remains controversial.
Shan Chong, Shan Chong, Qiufen Xie, Tiantian Ma, Qian Xiang, Ying Zhou, Yimin Cui   +6 more
doaj   +1 more source

Supplementary Material for: Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients

, 2021
Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-dependent (
Otsuka T. (4011287), Yamaguchi Y. (4158022), Akizawa T. (3588626), Tanaka-Amino K. (11538400)   +3 more
core   +1 more source